Literature DB >> 19740531

Validation of existing prognostic models in patients with early-stage cervical cancer.

Petra Biewenga1, Jacobus van der Velden, Ben Willem J Mol, Lukas J A Stalpers, Marten S Schilthuis, Jan Willem van der Steeg, Matthé P M Burger, Marrije R Buist.   

Abstract

OBJECTIVE: Models that predict survival and recurrence in patients with early-stage cervical cancer are important tools in patient management. We validated 12 existing prognostic models in an independent population of patients with early-stage cervical cancer.
MATERIALS AND METHODS: We searched the literature for prognostic models in patients with surgically treated early-stage cervical cancer. The prognostic performance of these models was assessed in a consecutive group of surgically treated patients with early-stage cervical cancer treated in our hospital between 1982 and 2004. The performance of the models was visually assessed with calibration plots, which display the relation between the predicted and observed survival.
RESULTS: Twelve published prognostic models met the inclusion criteria. The models categorized the patients into two to four risk groups. Prognostic factors most frequently used in these models were depth of invasion, lymph node metastasis, vascu/vascular space involvement, and tumor size. The models were validated in 563 consecutive patients with early-stage cervical cancer. All of the models underestimated the recurrence-free survival or disease-specific survival in our patients. Only two models performed reasonably well in our population. The use of more than three prognostic categories in the models was not meaningful.
CONCLUSION: In general, the models underestimated the survival. Only 2 of the 12 prognostic models for patients with early-stage cervical cancer were valid for the prediction of the recurrence-free or disease-specific survival in our patient population.

Entities:  

Mesh:

Year:  2009        PMID: 19740531     DOI: 10.1016/j.ygyno.2009.08.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Expression and prognostic significance of TAp73 and ΔNp73 in FIGO stage I-II cervical squamous cell carcinoma.

Authors:  Weipei Zhu; Xiaohong Pan; Zhujuan Yang; Pengfei Xing; Yongshen Zhang; Feng Li; Xueguan Lu
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

2.  Role of hypoxia-inducible factor-1α, carbonic anhydrase-IX, glucose transporter-1 and vascular endothelial growth factor associated with lymph node metastasis and recurrence in patients with locally advanced cervical cancer.

Authors:  Keita Iwasaki; Hiromitsu Yabushita; Taiki Ueno; Akihiko Wakatsuki
Journal:  Oncol Lett       Date:  2015-07-23       Impact factor: 2.967

Review 3.  Prognostic models for locally advanced cervical cancer: external validation of the published models.

Authors:  David Lora; Agustín Gómez de la Cámara; Sara Pedraza Fernández; Rafael Enríquez de Salamanca; José Fermín Pérez Regadera Gómez
Journal:  J Gynecol Oncol       Date:  2017-05-26       Impact factor: 4.401

4.  Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1.

Authors:  Isabel Freund; Stephanie Hehlgans; Daniel Martin; Michael Ensminger; Emmanouil Fokas; Claus Rödel; Markus Löbrich; Franz Rödel
Journal:  Cells       Date:  2020-05-16       Impact factor: 6.600

5.  Prognostic Model for Survival and Recurrence in Patients with Early-Stage Cervical Cancer: A Korean Gynecologic Oncology Group Study (KGOG 1028).

Authors:  E Sun Paik; Myong Cheol Lim; Moon-Hong Kim; Yun Hwan Kim; Eun Seop Song; Seok Ju Seong; Dong Hoon Suh; Jong-Min Lee; Chulmin Lee; Chel Hun Choi
Journal:  Cancer Res Treat       Date:  2019-08-05       Impact factor: 4.679

6.  Prognostic factors affecting survival and recurrence in patients with early cervical squamous cell cancer following radical hysterectomy.

Authors:  Dan Li; Xiaoxian Xu; Dingding Yan; Shuhui Yuan; Juan Ni; Hanmei Lou
Journal:  J Int Med Res       Date:  2019-12-31       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.